Mark P. Colonnese is CFO at Biota Pharmaceuticals, Inc. (BOTA). They have made 1 open-market trade across 1 company since 2016, most recently 2016-02-09.
CIK 0001040766
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BOTA | BUY | 2016-02-09 | 2016-02-09 | $1.41 | $10K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.